Ace Therapeutics utilizes advanced platform to help clients deliver data-rich insights in preclinical psychiatric studies. Our services that based on extensive platform enable clients to gain a comprehensive understanding of psychiatric disease mechanisms and discover potential innovative therapies.
Our Platform Technologies
A systematic introduction to Ace Therapeutics' preclinical capabilities and cutting-edge technology platforms.
Ace Therapeutics offers a diverse portfolio of rodent models and services for depression research.
The PCP-induced model uses NMDA antagonist PCP to mimic core schizophrenia symptoms in animals, studying disease mechanisms and treatments.
The Sucrose Preference Test (SPT) quantifies anhedonia, a core depression-related behavior in mice, by measuring reduced consumption of sucrose solution versus water.
Enter your E-mail and receive the latest news from us